 Alan Landay
Concepts (1143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 337 | 2023 | 1001 | 31.220 |
Why?
| | HIV-1 | 157 | 2022 | 447 | 12.320 |
Why?
| | CD4-Positive T-Lymphocytes | 98 | 2023 | 227 | 7.690 |
Why?
| | Anti-HIV Agents | 77 | 2022 | 171 | 6.640 |
Why?
| | Lymphocyte Activation | 84 | 2022 | 216 | 6.600 |
Why?
| | CD8-Positive T-Lymphocytes | 67 | 2022 | 179 | 5.390 |
Why?
| | Anti-Retroviral Agents | 25 | 2022 | 51 | 4.520 |
Why?
| | Antiretroviral Therapy, Highly Active | 60 | 2022 | 144 | 4.360 |
Why?
| | Microbiota | 18 | 2022 | 104 | 4.330 |
Why?
| | Monocytes | 43 | 2023 | 119 | 4.290 |
Why?
| | Humans | 501 | 2023 | 33050 | 3.860 |
Why?
| | Inflammation | 43 | 2023 | 397 | 3.770 |
Why?
| | Viral Load | 70 | 2022 | 206 | 3.760 |
Why?
| | T-Lymphocytes | 50 | 2022 | 229 | 3.760 |
Why?
| | HIV | 39 | 2022 | 99 | 3.600 |
Why?
| | Flow Cytometry | 69 | 2022 | 216 | 3.240 |
Why?
| | B-Lymphocytes | 21 | 2018 | 90 | 3.210 |
Why?
| | CD4 Lymphocyte Count | 78 | 2022 | 156 | 3.110 |
Why?
| | Intestinal Mucosa | 15 | 2021 | 231 | 2.990 |
Why?
| | Adult | 217 | 2021 | 9857 | 2.990 |
Why?
| | RNA, Viral | 59 | 2021 | 152 | 2.830 |
Why?
| | Female | 251 | 2023 | 18435 | 2.770 |
Why?
| | Killer Cells, Natural | 31 | 2023 | 93 | 2.720 |
Why?
| | Cytokines | 39 | 2023 | 372 | 2.640 |
Why?
| | Middle Aged | 177 | 2022 | 11223 | 2.580 |
Why?
| | T-Lymphocyte Subsets | 34 | 2022 | 88 | 2.500 |
Why?
| | Acquired Immunodeficiency Syndrome | 36 | 2021 | 99 | 2.450 |
Why?
| | Vagina | 20 | 2020 | 48 | 2.240 |
Why?
| | Immunophenotyping | 44 | 2021 | 79 | 2.240 |
Why?
| | Leukocytes, Mononuclear | 32 | 2023 | 98 | 2.220 |
Why?
| | Immunity, Innate | 20 | 2021 | 97 | 2.190 |
Why?
| | Carotid Artery Diseases | 14 | 2023 | 55 | 2.170 |
Why?
| | Lymphocyte Subsets | 19 | 2012 | 31 | 2.150 |
Why?
| | T-Lymphocytes, Regulatory | 17 | 2018 | 55 | 2.120 |
Why?
| | Atherosclerosis | 12 | 2023 | 78 | 1.980 |
Why?
| | Virus Replication | 31 | 2018 | 98 | 1.940 |
Why?
| | Aging | 25 | 2023 | 1638 | 1.940 |
Why?
| | Cytomegalovirus Infections | 10 | 2020 | 85 | 1.930 |
Why?
| | Male | 174 | 2023 | 17737 | 1.920 |
Why?
| | Antigens, CD | 36 | 2021 | 104 | 1.820 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 14 | 2023 | 24 | 1.820 |
Why?
| | Antibodies, Viral | 23 | 2023 | 94 | 1.810 |
Why?
| | Immunity, Mucosal | 8 | 2021 | 29 | 1.800 |
Why?
| | Interleukin-6 | 15 | 2023 | 123 | 1.730 |
Why?
| | HIV Seropositivity | 28 | 2015 | 98 | 1.680 |
Why?
| | Lymphocytes | 29 | 2020 | 117 | 1.600 |
Why?
| | Genitalia, Female | 13 | 2016 | 30 | 1.560 |
Why?
| | Gene Expression Regulation | 13 | 2021 | 350 | 1.550 |
Why?
| | Dysbiosis | 8 | 2020 | 64 | 1.440 |
Why?
| | Dendritic Cells | 14 | 2015 | 65 | 1.410 |
Why?
| | Cervix Uteri | 14 | 2015 | 39 | 1.410 |
Why?
| | Bacterial Translocation | 12 | 2021 | 33 | 1.360 |
Why?
| | Case-Control Studies | 34 | 2022 | 695 | 1.360 |
Why?
| | Cytomegalovirus | 14 | 2020 | 83 | 1.340 |
Why?
| | HIV Seronegativity | 17 | 2015 | 44 | 1.320 |
Why?
| | Bacteria | 7 | 2018 | 82 | 1.300 |
Why?
| | Mucous Membrane | 10 | 2015 | 42 | 1.270 |
Why?
| | AIDS Vaccines | 10 | 2022 | 14 | 1.200 |
Why?
| | Coinfection | 8 | 2016 | 33 | 1.190 |
Why?
| | Receptors, CXCR4 | 11 | 2019 | 28 | 1.190 |
Why?
| | Immunoglobulin G | 15 | 2023 | 149 | 1.170 |
Why?
| | Toll-Like Receptors | 6 | 2014 | 34 | 1.170 |
Why?
| | Receptors, CCR5 | 14 | 2008 | 27 | 1.160 |
Why?
| | GB virus C | 4 | 2013 | 6 | 1.150 |
Why?
| | Hepatitis C, Chronic | 10 | 2017 | 81 | 1.150 |
Why?
| | Vaginosis, Bacterial | 12 | 2017 | 30 | 1.130 |
Why?
| | B-Lymphocytes, Regulatory | 4 | 2017 | 8 | 1.130 |
Why?
| | Interleukins | 7 | 2023 | 43 | 1.130 |
Why?
| | Interleukin-10 | 12 | 2017 | 43 | 1.120 |
Why?
| | Cardiovascular Diseases | 14 | 2023 | 447 | 1.110 |
Why?
| | Gene Expression Profiling | 9 | 2022 | 182 | 1.090 |
Why?
| | Simian immunodeficiency virus | 11 | 2023 | 24 | 1.070 |
Why?
| | Cohort Studies | 40 | 2022 | 2079 | 1.050 |
Why?
| | Flaviviridae Infections | 3 | 2013 | 5 | 1.040 |
Why?
| | Hepatitis, Viral, Human | 5 | 2013 | 8 | 1.030 |
Why?
| | HIV Protease Inhibitors | 15 | 2020 | 21 | 1.030 |
Why?
| | Young Adult | 34 | 2021 | 2291 | 1.000 |
Why?
| | Neoplasms | 11 | 2021 | 281 | 0.990 |
Why?
| | Plasma | 9 | 2019 | 38 | 0.990 |
Why?
| | Epstein-Barr Virus Infections | 3 | 2020 | 18 | 0.980 |
Why?
| | Host-Pathogen Interactions | 7 | 2022 | 23 | 0.980 |
Why?
| | RNA, Ribosomal, 16S | 11 | 2021 | 56 | 0.940 |
Why?
| | Interleukin-2 | 22 | 2016 | 66 | 0.940 |
Why?
| | DNA, Viral | 23 | 2021 | 103 | 0.930 |
Why?
| | Viral Vaccines | 2 | 2022 | 5 | 0.920 |
Why?
| | Hepatitis C | 8 | 2016 | 70 | 0.920 |
Why?
| | Disease Progression | 22 | 2023 | 872 | 0.910 |
Why?
| | Aged | 51 | 2023 | 10546 | 0.900 |
Why?
| | Sexually Transmitted Diseases | 6 | 2016 | 18 | 0.880 |
Why?
| | Macrophages | 13 | 2021 | 138 | 0.870 |
Why?
| | Phenotype | 30 | 2023 | 386 | 0.870 |
Why?
| | T-Lymphocytes, Cytotoxic | 11 | 2016 | 38 | 0.860 |
Why?
| | Virology | 2 | 2020 | 14 | 0.860 |
Why?
| | Homeostasis | 5 | 2017 | 109 | 0.850 |
Why?
| | Signal Transduction | 8 | 2022 | 590 | 0.840 |
Why?
| | Viremia | 14 | 2020 | 37 | 0.840 |
Why?
| | Cross-Sectional Studies | 30 | 2022 | 1064 | 0.830 |
Why?
| | HIV Antibodies | 18 | 2017 | 42 | 0.830 |
Why?
| | Prospective Studies | 33 | 2023 | 2005 | 0.830 |
Why?
| | Food Hypersensitivity | 3 | 2021 | 57 | 0.820 |
Why?
| | Immune System | 6 | 2011 | 21 | 0.810 |
Why?
| | Reverse Transcriptase Inhibitors | 12 | 2010 | 24 | 0.800 |
Why?
| | Interleukin-7 | 9 | 2017 | 21 | 0.790 |
Why?
| | Zidovudine | 23 | 2003 | 39 | 0.780 |
Why?
| | Immunologic Memory | 11 | 2022 | 37 | 0.780 |
Why?
| | Adolescent | 39 | 2016 | 2692 | 0.770 |
Why?
| | HIV Long-Term Survivors | 4 | 2021 | 10 | 0.760 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 164 | 0.750 |
Why?
| | Dermatitis, Atopic | 4 | 2021 | 20 | 0.740 |
Why?
| | Pregnancy Complications, Infectious | 9 | 2003 | 35 | 0.730 |
Why?
| | Cells, Cultured | 29 | 2018 | 803 | 0.730 |
Why?
| | Polymerase Chain Reaction | 15 | 2017 | 184 | 0.720 |
Why?
| | B-Lymphocyte Subsets | 2 | 2017 | 6 | 0.720 |
Why?
| | Cyclohexanes | 6 | 2017 | 7 | 0.720 |
Why?
| | Influenza A virus | 3 | 2018 | 20 | 0.710 |
Why?
| | Interleukin-12 | 9 | 2016 | 43 | 0.710 |
Why?
| | Ritonavir | 13 | 2019 | 18 | 0.700 |
Why?
| | Triazoles | 6 | 2017 | 30 | 0.700 |
Why?
| | Influenza Vaccines | 2 | 2018 | 15 | 0.700 |
Why?
| | Inflammation Mediators | 8 | 2021 | 97 | 0.700 |
Why?
| | Body Fluids | 5 | 2016 | 21 | 0.690 |
Why?
| | Immunity, Cellular | 14 | 2020 | 71 | 0.690 |
Why?
| | Fungi | 2 | 2017 | 6 | 0.690 |
Why?
| | Lactobacillus | 8 | 2016 | 19 | 0.690 |
Why?
| | Immunologic Factors | 7 | 2019 | 53 | 0.680 |
Why?
| | Glycogen | 5 | 2016 | 12 | 0.680 |
Why?
| | Hepacivirus | 8 | 2016 | 73 | 0.680 |
Why?
| | Toll-Like Receptor 2 | 2 | 2015 | 37 | 0.670 |
Why?
| | Microbial Interactions | 1 | 2017 | 1 | 0.650 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2015 | 55 | 0.650 |
Why?
| | Adaptive Immunity | 2 | 2020 | 20 | 0.640 |
Why?
| | Plaque, Atherosclerotic | 7 | 2022 | 25 | 0.640 |
Why?
| | Cocaine | 3 | 2022 | 48 | 0.640 |
Why?
| | Apoptosis | 8 | 2014 | 288 | 0.640 |
Why?
| | Influenza, Human | 1 | 2018 | 53 | 0.630 |
Why?
| | Liver Cirrhosis | 5 | 2016 | 61 | 0.630 |
Why?
| | HLA-DR Antigens | 16 | 2013 | 27 | 0.630 |
Why?
| | Carotid Stenosis | 3 | 2023 | 36 | 0.620 |
Why?
| | Interferon-gamma | 17 | 2018 | 119 | 0.620 |
Why?
| | Blood Coagulation | 2 | 2014 | 28 | 0.620 |
Why?
| | Carotid Arteries | 11 | 2023 | 62 | 0.610 |
Why?
| | Receptors, Antigen, T-Cell | 8 | 2013 | 30 | 0.610 |
Why?
| | Papillomavirus Infections | 3 | 2014 | 38 | 0.610 |
Why?
| | Animals | 33 | 2023 | 5378 | 0.600 |
Why?
| | HIV Antigens | 12 | 2016 | 23 | 0.600 |
Why?
| | Immunotherapy | 6 | 2020 | 76 | 0.590 |
Why?
| | Drug Therapy, Combination | 22 | 2019 | 261 | 0.580 |
Why?
| | CD4-CD8 Ratio | 11 | 2019 | 16 | 0.570 |
Why?
| | Osteoporosis | 2 | 2016 | 79 | 0.570 |
Why?
| | Lymphocyte Count | 18 | 2017 | 38 | 0.570 |
Why?
| | Colon | 5 | 2018 | 160 | 0.560 |
Why?
| | Immunoassay | 5 | 2011 | 47 | 0.550 |
Why?
| | Fractures, Bone | 1 | 2016 | 72 | 0.540 |
Why?
| | Benzoxazines | 4 | 2019 | 9 | 0.530 |
Why?
| | Intestines | 5 | 2021 | 115 | 0.520 |
Why?
| | Membrane Proteins | 2 | 2017 | 220 | 0.500 |
Why?
| | Lactoferrin | 2 | 2011 | 16 | 0.490 |
Why?
| | Epithelial Cells | 1 | 2014 | 107 | 0.490 |
Why?
| | Anti-Inflammatory Agents | 3 | 2021 | 111 | 0.490 |
Why?
| | Interleukin-1beta | 2 | 2011 | 59 | 0.490 |
Why?
| | Glucose Transporter Type 1 | 4 | 2018 | 8 | 0.490 |
Why?
| | DNA, Bacterial | 8 | 2017 | 53 | 0.490 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2014 | 53 | 0.480 |
Why?
| | Cell Differentiation | 8 | 2021 | 181 | 0.480 |
Why?
| | Vaccines | 2 | 2023 | 12 | 0.470 |
Why?
| | Toll-Like Receptor 7 | 3 | 2011 | 5 | 0.470 |
Why?
| | Tuberculosis | 2 | 2023 | 26 | 0.460 |
Why?
| | Antigen-Presenting Cells | 4 | 2014 | 19 | 0.450 |
Why?
| | Imidazoles | 2 | 2016 | 73 | 0.450 |
Why?
| | Menstrual Cycle | 7 | 2015 | 29 | 0.450 |
Why?
| | Receptors, Tumor Necrosis Factor | 3 | 2010 | 40 | 0.450 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 4 | 2022 | 9 | 0.450 |
Why?
| | United States | 20 | 2022 | 2634 | 0.450 |
Why?
| | Receptors, IgG | 7 | 2021 | 20 | 0.440 |
Why?
| | Metagenome | 6 | 2021 | 22 | 0.440 |
Why?
| | Antigens, Surface | 13 | 2003 | 26 | 0.440 |
Why?
| | Genital Diseases, Female | 3 | 2008 | 11 | 0.440 |
Why?
| | Thromboplastin | 3 | 2019 | 7 | 0.440 |
Why?
| | Withholding Treatment | 3 | 2021 | 10 | 0.440 |
Why?
| | Anti-Infective Agents | 1 | 2012 | 63 | 0.440 |
Why?
| | Antibody Formation | 4 | 2022 | 41 | 0.440 |
Why?
| | Infectious Disease Transmission, Vertical | 5 | 2005 | 20 | 0.430 |
Why?
| | Saliva | 5 | 2015 | 62 | 0.430 |
Why?
| | Cocaine-Related Disorders | 2 | 2022 | 19 | 0.430 |
Why?
| | Caspase 3 | 2 | 2016 | 31 | 0.420 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 7 | 2015 | 17 | 0.420 |
Why?
| | Thymus Gland | 6 | 2014 | 23 | 0.420 |
Why?
| | Interferon-alpha | 7 | 2012 | 69 | 0.420 |
Why?
| | Oligodeoxyribonucleotides | 3 | 2009 | 10 | 0.420 |
Why?
| | Biopsy | 6 | 2019 | 277 | 0.410 |
Why?
| | Pilot Projects | 10 | 2019 | 467 | 0.410 |
Why?
| | Receptors, Cell Surface | 7 | 2015 | 55 | 0.410 |
Why?
| | Pyrimidinones | 2 | 2010 | 4 | 0.410 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 10 | 2017 | 148 | 0.410 |
Why?
| | Antigens, Differentiation | 8 | 2017 | 20 | 0.400 |
Why?
| | Sequence Analysis, DNA | 8 | 2017 | 81 | 0.400 |
Why?
| | Membrane Glycoproteins | 11 | 2017 | 109 | 0.400 |
Why?
| | Vaginal Douching | 4 | 2014 | 9 | 0.400 |
Why?
| | Leukocyte Count | 12 | 2002 | 96 | 0.390 |
Why?
| | Antiviral Agents | 7 | 2016 | 133 | 0.390 |
Why?
| | Symbiosis | 3 | 2020 | 5 | 0.380 |
Why?
| | Antibodies, Neutralizing | 4 | 2023 | 30 | 0.380 |
Why?
| | Orphan Nuclear Receptors | 1 | 2009 | 3 | 0.380 |
Why?
| | Vascular Stiffness | 3 | 2023 | 9 | 0.370 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2009 | 20 | 0.370 |
Why?
| | Tumor Necrosis Factor-alpha | 8 | 2011 | 229 | 0.370 |
Why?
| | Risk Factors | 19 | 2023 | 2765 | 0.370 |
Why?
| | Chloroquine | 3 | 2016 | 13 | 0.360 |
Why?
| | Chronic Disease | 9 | 2016 | 554 | 0.360 |
Why?
| | Cell Division | 10 | 2009 | 123 | 0.360 |
Why?
| | Cell Proliferation | 8 | 2018 | 232 | 0.360 |
Why?
| | NF-kappa B | 5 | 2022 | 119 | 0.360 |
Why?
| | Longitudinal Studies | 13 | 2022 | 1486 | 0.350 |
Why?
| | Infant, Newborn, Diseases | 3 | 2005 | 19 | 0.350 |
Why?
| | Interleukin-17 | 4 | 2021 | 29 | 0.350 |
Why?
| | Galectins | 2 | 2021 | 7 | 0.350 |
Why?
| | RNA, Messenger | 7 | 2021 | 376 | 0.340 |
Why?
| | Carotid Intima-Media Thickness | 5 | 2021 | 24 | 0.340 |
Why?
| | Mycobacterium tuberculosis | 3 | 2022 | 17 | 0.340 |
Why?
| | Toll-Like Receptor 8 | 1 | 2008 | 2 | 0.330 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2008 | 8 | 0.330 |
Why?
| | Virus Latency | 5 | 2021 | 16 | 0.330 |
Why?
| | Quinolines | 1 | 2008 | 18 | 0.330 |
Why?
| | Biomedical Research | 2 | 2020 | 95 | 0.330 |
Why?
| | Aged, 80 and over | 15 | 2021 | 5253 | 0.330 |
Why?
| | Interleukin-8 | 4 | 2015 | 41 | 0.330 |
Why?
| | Diet | 3 | 2018 | 228 | 0.330 |
Why?
| | Pregnancy | 11 | 2004 | 466 | 0.330 |
Why?
| | HIV Integrase Inhibitors | 2 | 2019 | 6 | 0.330 |
Why?
| | DNA | 7 | 2018 | 142 | 0.320 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 8 | 2006 | 17 | 0.320 |
Why?
| | Infant | 11 | 2021 | 662 | 0.320 |
Why?
| | Time Factors | 16 | 2021 | 1873 | 0.320 |
Why?
| | Toll-Like Receptor 9 | 3 | 2017 | 10 | 0.310 |
Why?
| | Fatty Acids, Volatile | 2 | 2021 | 30 | 0.310 |
Why?
| | Risk-Taking | 1 | 2007 | 41 | 0.310 |
Why?
| | Lamivudine | 11 | 2007 | 18 | 0.310 |
Why?
| | Glucose | 3 | 2022 | 78 | 0.300 |
Why?
| | Specimen Handling | 3 | 2008 | 51 | 0.300 |
Why?
| | Ileum | 2 | 2017 | 29 | 0.290 |
Why?
| | Interferon Type I | 3 | 2018 | 20 | 0.290 |
Why?
| | Lymphoid Tissue | 5 | 2017 | 19 | 0.290 |
Why?
| | Clinical Laboratory Techniques | 4 | 2011 | 38 | 0.290 |
Why?
| | Trichomonas vaginalis | 3 | 2015 | 3 | 0.280 |
Why?
| | HIV Core Protein p24 | 10 | 2007 | 29 | 0.280 |
Why?
| | Interleukin-4 | 4 | 2022 | 36 | 0.270 |
Why?
| | Antibodies, Monoclonal | 18 | 2007 | 293 | 0.270 |
Why?
| | DNA, Ribosomal | 5 | 2017 | 12 | 0.270 |
Why?
| | Adjuvants, Immunologic | 5 | 2018 | 27 | 0.270 |
Why?
| | Health Services Accessibility | 2 | 2022 | 116 | 0.270 |
Why?
| | C-Reactive Protein | 7 | 2010 | 140 | 0.270 |
Why?
| | Myocardial Infarction | 3 | 2021 | 194 | 0.260 |
Why?
| | Neutralization Tests | 3 | 2022 | 11 | 0.260 |
Why?
| | Immunity | 5 | 2019 | 26 | 0.260 |
Why?
| | Gastrointestinal Tract | 3 | 2021 | 56 | 0.260 |
Why?
| | Cryopreservation | 2 | 2006 | 25 | 0.260 |
Why?
| | Immune Tolerance | 2 | 2013 | 22 | 0.260 |
Why?
| | Age Factors | 8 | 2018 | 931 | 0.260 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 7 | 2023 | 28 | 0.260 |
Why?
| | Semen | 2 | 2008 | 5 | 0.260 |
Why?
| | Polyamines | 2 | 2014 | 2 | 0.260 |
Why?
| | T-Lymphocytes, Helper-Inducer | 13 | 2017 | 26 | 0.260 |
Why?
| | Infant, Newborn | 12 | 2006 | 761 | 0.260 |
Why?
| | Histocompatibility Antigens Class II | 3 | 2018 | 15 | 0.250 |
Why?
| | Risk Assessment | 5 | 2021 | 814 | 0.250 |
Why?
| | Rectum | 3 | 2019 | 72 | 0.250 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 178 | 0.250 |
Why?
| | Comorbidity | 7 | 2022 | 565 | 0.250 |
Why?
| | Trichomonas Vaginitis | 2 | 2015 | 3 | 0.250 |
Why?
| | Transcriptome | 2 | 2022 | 90 | 0.250 |
Why?
| | Serotonin | 1 | 2023 | 43 | 0.240 |
Why?
| | Up-Regulation | 9 | 2019 | 225 | 0.240 |
Why?
| | Gene Expression Regulation, Viral | 4 | 1999 | 15 | 0.240 |
Why?
| | Vaccination | 5 | 2018 | 45 | 0.240 |
Why?
| | Peptide Fragments | 3 | 2018 | 118 | 0.240 |
Why?
| | Progesterone | 4 | 2016 | 29 | 0.240 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 3 | 2013 | 8 | 0.240 |
Why?
| | AIDS Dementia Complex | 3 | 2019 | 41 | 0.240 |
Why?
| | Hip Fractures | 1 | 2023 | 30 | 0.240 |
Why?
| | GPI-Linked Proteins | 4 | 2021 | 24 | 0.240 |
Why?
| | HIV Envelope Protein gp41 | 3 | 2017 | 12 | 0.240 |
Why?
| | Base Sequence | 10 | 2014 | 163 | 0.230 |
Why?
| | Mice | 10 | 2023 | 1965 | 0.230 |
Why?
| | Interleukin-15 | 3 | 2011 | 11 | 0.230 |
Why?
| | Rhinitis | 2 | 2016 | 177 | 0.230 |
Why?
| | Tuberculosis Vaccines | 1 | 2022 | 2 | 0.230 |
Why?
| | Kynurenine | 2 | 2022 | 3 | 0.230 |
Why?
| | Duodenum | 2 | 2019 | 13 | 0.230 |
Why?
| | Dideoxynucleosides | 3 | 2010 | 4 | 0.230 |
Why?
| | Chemokine CCL5 | 4 | 2008 | 20 | 0.230 |
Why?
| | Herpesvirus 4, Human | 3 | 2020 | 17 | 0.230 |
Why?
| | Substance-Related Disorders | 2 | 2003 | 119 | 0.230 |
Why?
| | Pandemics | 2 | 2022 | 253 | 0.230 |
Why?
| | Viral Envelope Proteins | 4 | 2013 | 21 | 0.220 |
Why?
| | Cell Separation | 8 | 2015 | 45 | 0.220 |
Why?
| | Stroke | 3 | 2022 | 406 | 0.220 |
Why?
| | Sinusitis | 2 | 2016 | 201 | 0.220 |
Why?
| | beta-Glucans | 1 | 2022 | 26 | 0.220 |
Why?
| | Complement System Proteins | 5 | 1999 | 16 | 0.220 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 2 | 2023 | 104 | 0.220 |
Why?
| | Coculture Techniques | 4 | 2014 | 38 | 0.220 |
Why?
| | Trophoblasts | 1 | 2002 | 3 | 0.220 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2020 | 33 | 0.220 |
Why?
| | Virus Shedding | 5 | 2016 | 13 | 0.220 |
Why?
| | Follow-Up Studies | 8 | 2022 | 2055 | 0.220 |
Why?
| | Methamphetamine | 1 | 2022 | 48 | 0.210 |
Why?
| | Developing Countries | 4 | 2014 | 24 | 0.210 |
Why?
| | Continuity of Patient Care | 1 | 2022 | 30 | 0.210 |
Why?
| | Succinic Acid | 1 | 2021 | 1 | 0.210 |
Why?
| | Th17 Cells | 2 | 2021 | 34 | 0.210 |
Why?
| | Protein Isoforms | 4 | 2023 | 62 | 0.210 |
Why?
| | Recombinant Proteins | 11 | 2019 | 289 | 0.210 |
Why?
| | Caproates | 1 | 2021 | 1 | 0.210 |
Why?
| | Laboratories | 3 | 2008 | 27 | 0.210 |
Why?
| | Asymptomatic Diseases | 4 | 2019 | 21 | 0.210 |
Why?
| | Colon, Sigmoid | 2 | 2020 | 18 | 0.210 |
Why?
| | Phospholipids | 1 | 2021 | 10 | 0.210 |
Why?
| | Sex Factors | 5 | 2021 | 548 | 0.200 |
Why?
| | Sex Characteristics | 1 | 2022 | 139 | 0.200 |
Why?
| | Schistosomiasis | 1 | 2021 | 9 | 0.200 |
Why?
| | Double-Blind Method | 8 | 2019 | 548 | 0.200 |
Why?
| | Adipose Tissue | 2 | 2019 | 99 | 0.200 |
Why?
| | Podocytes | 1 | 2023 | 181 | 0.200 |
Why?
| | Cell Line, Tumor | 2 | 2014 | 287 | 0.200 |
Why?
| | In Vitro Techniques | 11 | 2004 | 244 | 0.200 |
Why?
| | Sulfonamides | 2 | 2012 | 60 | 0.200 |
Why?
| | Menopause | 1 | 2022 | 131 | 0.200 |
Why?
| | Palatine Tonsil | 3 | 2000 | 7 | 0.200 |
Why?
| | Virus Activation | 2 | 2021 | 11 | 0.200 |
Why?
| | Down-Regulation | 4 | 2019 | 131 | 0.200 |
Why?
| | Child, Preschool | 7 | 2021 | 799 | 0.190 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2020 | 3 | 0.190 |
Why?
| | Immunoglobulin A | 3 | 2017 | 20 | 0.190 |
Why?
| | Models, Animal | 2 | 2012 | 147 | 0.190 |
Why?
| | Body Mass Index | 3 | 2019 | 478 | 0.190 |
Why?
| | Inflammasomes | 1 | 2020 | 19 | 0.190 |
Why?
| | Fluorescent Antibody Technique | 8 | 2007 | 87 | 0.190 |
Why?
| | Ultrasonography | 6 | 2019 | 216 | 0.190 |
Why?
| | Occupational Exposure | 6 | 1999 | 27 | 0.190 |
Why?
| | Congresses as Topic | 1 | 2020 | 36 | 0.190 |
Why?
| | Incidence | 5 | 2023 | 841 | 0.190 |
Why?
| | Immunity, Humoral | 2 | 2017 | 10 | 0.190 |
Why?
| | Drug Resistance, Viral | 4 | 2012 | 39 | 0.190 |
Why?
| | Lung | 1 | 2021 | 180 | 0.190 |
Why?
| | Health Personnel | 5 | 2022 | 120 | 0.190 |
Why?
| | Diabetes Complications | 1 | 2020 | 70 | 0.190 |
Why?
| | Staining and Labeling | 3 | 2014 | 27 | 0.190 |
Why?
| | Diet, High-Fat | 1 | 2019 | 29 | 0.190 |
Why?
| | Complement Activation | 7 | 2021 | 15 | 0.190 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 86 | 0.190 |
Why?
| | Cell Communication | 2 | 2012 | 38 | 0.180 |
Why?
| | Cells | 1 | 2019 | 5 | 0.180 |
Why?
| | Disease | 1 | 2019 | 8 | 0.180 |
Why?
| | Receptors, CXCR5 | 2 | 2016 | 2 | 0.180 |
Why?
| | Postpartum Period | 2 | 1999 | 28 | 0.180 |
Why?
| | Coronary Disease | 1 | 2020 | 101 | 0.180 |
Why?
| | Carnitine | 1 | 2019 | 8 | 0.180 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2019 | 41 | 0.180 |
Why?
| | Treatment Outcome | 13 | 2019 | 4041 | 0.180 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 2 | 2017 | 6 | 0.180 |
Why?
| | Blood Pressure | 1 | 2021 | 270 | 0.180 |
Why?
| | Proviruses | 6 | 2000 | 9 | 0.180 |
Why?
| | Ceramides | 1 | 2019 | 15 | 0.180 |
Why?
| | Estrogens | 2 | 2016 | 33 | 0.180 |
Why?
| | Bone Resorption | 2 | 2019 | 106 | 0.180 |
Why?
| | Leukocytes | 3 | 2015 | 49 | 0.180 |
Why?
| | Antigens, Viral | 8 | 2010 | 21 | 0.180 |
Why?
| | Cell Line | 14 | 2018 | 354 | 0.180 |
Why?
| | Therapeutic Irrigation | 7 | 2014 | 69 | 0.180 |
Why?
| | Lipopolysaccharides | 7 | 2014 | 140 | 0.180 |
Why?
| | Central Nervous System | 1 | 2019 | 67 | 0.180 |
Why?
| | Didanosine | 2 | 1998 | 6 | 0.180 |
Why?
| | Chemokines | 3 | 2012 | 32 | 0.170 |
Why?
| | Immunomodulation | 1 | 2019 | 12 | 0.170 |
Why?
| | CCR5 Receptor Antagonists | 2 | 2016 | 2 | 0.170 |
Why?
| | Food Supply | 1 | 2019 | 16 | 0.170 |
Why?
| | Premenopause | 2 | 2016 | 22 | 0.170 |
Why?
| | Methylamines | 1 | 2018 | 4 | 0.170 |
Why?
| | Sensitivity and Specificity | 7 | 2022 | 592 | 0.170 |
Why?
| | Receptors, Fc | 3 | 2021 | 11 | 0.170 |
Why?
| | Apolipoprotein B-100 | 1 | 2018 | 1 | 0.170 |
Why?
| | Apolipoproteins B | 1 | 2018 | 3 | 0.170 |
Why?
| | Choline | 1 | 2018 | 7 | 0.170 |
Why?
| | Decision Making | 1 | 2021 | 239 | 0.170 |
Why?
| | Disease Models, Animal | 4 | 2018 | 844 | 0.170 |
Why?
| | Biodiversity | 3 | 2020 | 37 | 0.170 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 18 | 0.170 |
Why?
| | Vitamin D | 1 | 2019 | 36 | 0.170 |
Why?
| | Tryptophan | 1 | 2018 | 13 | 0.170 |
Why?
| | Chemokine CXCL10 | 4 | 2015 | 9 | 0.170 |
Why?
| | Drug Administration Schedule | 6 | 2012 | 249 | 0.170 |
Why?
| | Galactose | 1 | 2018 | 4 | 0.170 |
Why?
| | Rifamycins | 2 | 2016 | 2 | 0.170 |
Why?
| | Lipids | 2 | 2023 | 57 | 0.170 |
Why?
| | Sexual Behavior | 4 | 2014 | 78 | 0.170 |
Why?
| | Fatigue Syndrome, Chronic | 3 | 1994 | 7 | 0.170 |
Why?
| | Transcriptional Activation | 1 | 1998 | 29 | 0.170 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 32 | 0.160 |
Why?
| | Herpesvirus 2, Human | 1 | 2017 | 1 | 0.160 |
Why?
| | Biological Therapy | 1 | 2018 | 6 | 0.160 |
Why?
| | Herpes Genitalis | 1 | 2017 | 4 | 0.160 |
Why?
| | Hypertension | 1 | 2021 | 294 | 0.160 |
Why?
| | Ulcer | 1 | 2017 | 8 | 0.160 |
Why?
| | alpha-Amylases | 2 | 2015 | 3 | 0.160 |
Why?
| | Drug Discovery | 1 | 2018 | 23 | 0.160 |
Why?
| | Child | 7 | 2021 | 1639 | 0.160 |
Why?
| | Autoimmunity | 1 | 2017 | 22 | 0.160 |
Why?
| | Antibodies | 5 | 2023 | 77 | 0.160 |
Why?
| | Alkynes | 4 | 2019 | 9 | 0.160 |
Why?
| | Bone and Bones | 1 | 2018 | 128 | 0.160 |
Why?
| | Cyclopropanes | 4 | 2019 | 26 | 0.160 |
Why?
| | Dietary Fiber | 1 | 2017 | 25 | 0.160 |
Why?
| | Cytotoxicity, Immunologic | 6 | 1990 | 33 | 0.160 |
Why?
| | Clinical Trials as Topic | 6 | 2015 | 368 | 0.160 |
Why?
| | Cell Cycle | 5 | 2012 | 47 | 0.150 |
Why?
| | Virus Diseases | 3 | 2023 | 18 | 0.150 |
Why?
| | Cholesterol, LDL | 2 | 2014 | 46 | 0.150 |
Why?
| | Metabolomics | 3 | 2021 | 24 | 0.150 |
Why?
| | Butyrates | 1 | 2017 | 20 | 0.150 |
Why?
| | Valproic Acid | 2 | 2008 | 32 | 0.150 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2020 | 230 | 0.150 |
Why?
| | Arenaviridae Infections | 1 | 2016 | 2 | 0.150 |
Why?
| | Lymphocytic choriomeningitis virus | 1 | 2016 | 2 | 0.150 |
Why?
| | Receptors, HIV | 4 | 2017 | 6 | 0.150 |
Why?
| | Kidney | 1 | 2018 | 219 | 0.150 |
Why?
| | Global Health | 2 | 2006 | 61 | 0.150 |
Why?
| | Cholesterol, HDL | 2 | 2013 | 32 | 0.150 |
Why?
| | Smoking | 4 | 2023 | 208 | 0.150 |
Why?
| | Reproducibility of Results | 9 | 2014 | 896 | 0.150 |
Why?
| | Australia | 2 | 2014 | 49 | 0.150 |
Why?
| | Loneliness | 1 | 2017 | 54 | 0.150 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2016 | 35 | 0.150 |
Why?
| | Education | 1 | 2016 | 41 | 0.150 |
Why?
| | Viral Tropism | 1 | 2016 | 4 | 0.150 |
Why?
| | Multivariate Analysis | 6 | 2019 | 386 | 0.150 |
Why?
| | Vaccines, DNA | 1 | 2016 | 10 | 0.140 |
Why?
| | Antibody Specificity | 3 | 2021 | 56 | 0.140 |
Why?
| | Thrombophilia | 1 | 2016 | 9 | 0.140 |
Why?
| | Asthma | 2 | 2016 | 194 | 0.140 |
Why?
| | Neutrophils | 4 | 2011 | 139 | 0.140 |
Why?
| | Nasal Mucosa | 1 | 2016 | 19 | 0.140 |
Why?
| | Predictive Value of Tests | 4 | 2021 | 626 | 0.140 |
Why?
| | Transcription, Genetic | 5 | 2019 | 129 | 0.140 |
Why?
| | Multicenter Studies as Topic | 4 | 2019 | 78 | 0.140 |
Why?
| | Macrophage Inflammatory Proteins | 4 | 2011 | 9 | 0.140 |
Why?
| | Propidium | 2 | 2014 | 4 | 0.140 |
Why?
| | Osteogenesis | 1 | 2016 | 102 | 0.140 |
Why?
| | Macaca nemestrina | 4 | 2017 | 4 | 0.140 |
Why?
| | Linear Models | 4 | 2019 | 275 | 0.140 |
Why?
| | Metagenomics | 3 | 2021 | 6 | 0.140 |
Why?
| | Postmenopause | 1 | 2015 | 67 | 0.140 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2015 | 13 | 0.130 |
Why?
| | Hepatitis B, Chronic | 1 | 2015 | 7 | 0.130 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 12 | 0.130 |
Why?
| | Genes, env | 3 | 2011 | 5 | 0.130 |
Why?
| | HIV Long Terminal Repeat | 4 | 1999 | 16 | 0.130 |
Why?
| | Models, Biological | 3 | 2013 | 397 | 0.130 |
Why?
| | Nasal Polyps | 1 | 2016 | 66 | 0.130 |
Why?
| | Toll-Like Receptor 4 | 2 | 2012 | 34 | 0.130 |
Why?
| | Quality Control | 6 | 1994 | 52 | 0.130 |
Why?
| | Prognosis | 6 | 2021 | 1011 | 0.130 |
Why?
| | Caspases | 1 | 2014 | 32 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 3 | 1988 | 40 | 0.130 |
Why?
| | Regression Analysis | 3 | 2020 | 326 | 0.130 |
Why?
| | Antibodies, Bacterial | 1 | 2014 | 25 | 0.130 |
Why?
| | Hypersensitivity, Delayed | 4 | 2003 | 22 | 0.130 |
Why?
| | MicroRNAs | 1 | 2015 | 63 | 0.130 |
Why?
| | Fibroblast Growth Factor 7 | 1 | 2014 | 2 | 0.130 |
Why?
| | Anti-Bacterial Agents | 2 | 2016 | 436 | 0.130 |
Why?
| | Lipoproteins, LDL | 1 | 2014 | 8 | 0.130 |
Why?
| | CD40 Ligand | 2 | 2013 | 8 | 0.130 |
Why?
| | Receptors, Interleukin-10 | 1 | 2014 | 2 | 0.130 |
Why?
| | Homosexuality | 3 | 1990 | 9 | 0.130 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 6 | 2007 | 6 | 0.130 |
Why?
| | Solubility | 7 | 2015 | 38 | 0.130 |
Why?
| | Antigens | 2 | 1998 | 28 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 4 | 1996 | 381 | 0.130 |
Why?
| | Dried Blood Spot Testing | 1 | 2014 | 4 | 0.130 |
Why?
| | Bone Density | 1 | 2015 | 144 | 0.130 |
Why?
| | Apoptosis Regulatory Proteins | 3 | 2009 | 21 | 0.120 |
Why?
| | Cardiovascular Agents | 1 | 2014 | 33 | 0.120 |
Why?
| | Cytological Techniques | 1 | 1993 | 17 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2014 | 42 | 0.120 |
Why?
| | Molecular Sequence Data | 9 | 2003 | 312 | 0.120 |
Why?
| | Aging, Premature | 1 | 2013 | 1 | 0.120 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 2000 | 49 | 0.120 |
Why?
| | Phylogeny | 5 | 2017 | 68 | 0.120 |
Why?
| | Early Diagnosis | 1 | 2014 | 75 | 0.120 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2013 | 6 | 0.120 |
Why?
| | Writing | 1 | 1994 | 23 | 0.120 |
Why?
| | Endotoxemia | 1 | 2014 | 29 | 0.120 |
Why?
| | Th2 Cells | 2 | 2007 | 29 | 0.120 |
Why?
| | Hydrogen-Ion Concentration | 4 | 2016 | 174 | 0.120 |
Why?
| | Ligands | 3 | 2011 | 58 | 0.120 |
Why?
| | Gene Products, gag | 2 | 2006 | 5 | 0.120 |
Why?
| | Receptors, Interleukin-2 | 4 | 2006 | 11 | 0.120 |
Why?
| | Glioma | 3 | 1983 | 53 | 0.120 |
Why?
| | Trichomonas Infections | 1 | 2013 | 3 | 0.120 |
Why?
| | Rwanda | 2 | 2014 | 3 | 0.120 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1993 | 20 | 0.120 |
Why?
| | Genes, pol | 2 | 2003 | 3 | 0.120 |
Why?
| | Cytoplasm | 1 | 1993 | 39 | 0.110 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2012 | 3 | 0.110 |
Why?
| | Lymphoproliferative Disorders | 3 | 1988 | 21 | 0.110 |
Why?
| | Graft vs Host Disease | 1 | 2013 | 60 | 0.110 |
Why?
| | Hyperlipidemias | 1 | 2012 | 26 | 0.110 |
Why?
| | Cause of Death | 1 | 2013 | 83 | 0.110 |
Why?
| | Antigens, CD1 | 3 | 2015 | 6 | 0.110 |
Why?
| | Chemokine CCL4 | 3 | 2007 | 8 | 0.110 |
Why?
| | Hospitalization | 1 | 2016 | 368 | 0.110 |
Why?
| | Chemokine CCL3 | 3 | 2007 | 14 | 0.110 |
Why?
| | Myeloid Cells | 1 | 2012 | 19 | 0.110 |
Why?
| | Phytohemagglutinins | 5 | 2001 | 9 | 0.110 |
Why?
| | Primates | 1 | 2012 | 17 | 0.110 |
Why?
| | Frail Elderly | 2 | 2023 | 54 | 0.110 |
Why?
| | Kenya | 3 | 2021 | 7 | 0.110 |
Why?
| | beta 2-Microglobulin | 2 | 1992 | 3 | 0.110 |
Why?
| | Cholesterol | 1 | 2012 | 70 | 0.110 |
Why?
| | Health Services Research | 1 | 2012 | 44 | 0.110 |
Why?
| | Oligopeptides | 1 | 2012 | 34 | 0.110 |
Why?
| | Genotype | 6 | 2016 | 422 | 0.110 |
Why?
| | Pyridines | 1 | 2012 | 47 | 0.110 |
Why?
| | Disease Susceptibility | 5 | 2016 | 87 | 0.110 |
Why?
| | Lysophosphatidylcholines | 2 | 2022 | 7 | 0.110 |
Why?
| | Tetanus Toxoid | 4 | 2014 | 10 | 0.110 |
Why?
| | Brain Neoplasms | 3 | 1983 | 178 | 0.110 |
Why?
| | Complement Pathway, Classical | 4 | 1999 | 5 | 0.110 |
Why?
| | DNA, Neoplasm | 2 | 1988 | 31 | 0.110 |
Why?
| | Hepatitis C Antibodies | 2 | 2008 | 7 | 0.110 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2009 | 24 | 0.110 |
Why?
| | Glycomics | 2 | 2021 | 5 | 0.110 |
Why?
| | Serum | 1 | 2011 | 10 | 0.110 |
Why?
| | Neopterin | 4 | 2015 | 4 | 0.100 |
Why?
| | Chlamydia Infections | 2 | 2008 | 8 | 0.100 |
Why?
| | Alzheimer Disease | 2 | 2013 | 1992 | 0.100 |
Why?
| | Biopterin | 1 | 1991 | 1 | 0.100 |
Why?
| | 2',5'-Oligoadenylate Synthetase | 1 | 1991 | 1 | 0.100 |
Why?
| | CTLA-4 Antigen | 2 | 2008 | 7 | 0.100 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2011 | 2 | 0.100 |
Why?
| | Macaca mulatta | 5 | 2013 | 70 | 0.100 |
Why?
| | Lopinavir | 2 | 2010 | 2 | 0.100 |
Why?
| | DNA Primers | 3 | 2000 | 61 | 0.100 |
Why?
| | Bacterial Physiological Phenomena | 1 | 2010 | 2 | 0.100 |
Why?
| | Retrospective Studies | 7 | 2022 | 3841 | 0.100 |
Why?
| | Placenta | 2 | 2001 | 16 | 0.100 |
Why?
| | Prevalence | 4 | 2021 | 554 | 0.100 |
Why?
| | Viral Core Proteins | 1 | 1990 | 6 | 0.100 |
Why?
| | Hematopoietic Stem Cells | 3 | 2000 | 14 | 0.100 |
Why?
| | Caspase 8 | 1 | 2010 | 14 | 0.100 |
Why?
| | Cell Survival | 4 | 2014 | 185 | 0.100 |
Why?
| | Adoptive Transfer | 2 | 2002 | 49 | 0.100 |
Why?
| | Immunocompromised Host | 2 | 2021 | 54 | 0.100 |
Why?
| | Blood Specimen Collection | 2 | 2006 | 13 | 0.100 |
Why?
| | Immunization | 3 | 2015 | 50 | 0.100 |
Why?
| | Cell Count | 2 | 2008 | 114 | 0.100 |
Why?
| | Oxygen Consumption | 2 | 1989 | 65 | 0.100 |
Why?
| | Monkey Diseases | 1 | 2010 | 1 | 0.100 |
Why?
| | ADP-ribosyl Cyclase | 3 | 2000 | 5 | 0.100 |
Why?
| | Women's Health | 4 | 2017 | 247 | 0.100 |
Why?
| | Cross-Over Studies | 2 | 2023 | 86 | 0.090 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2000 | 12 | 0.090 |
Why?
| | Receptors, Interleukin-7 | 2 | 2006 | 3 | 0.090 |
Why?
| | Hydrocarbons, Fluorinated | 1 | 2009 | 3 | 0.090 |
Why?
| | Acute Disease | 2 | 2007 | 258 | 0.090 |
Why?
| | Bacterial Infections | 2 | 2021 | 71 | 0.090 |
Why?
| | Cluster Analysis | 3 | 2017 | 60 | 0.090 |
Why?
| | Cytoplasmic Granules | 3 | 1999 | 11 | 0.090 |
Why?
| | Receptors, Immunologic | 2 | 2007 | 34 | 0.090 |
Why?
| | Macaca | 3 | 2015 | 4 | 0.090 |
Why?
| | SAIDS Vaccines | 1 | 2009 | 1 | 0.090 |
Why?
| | Virus Inactivation | 1 | 2009 | 1 | 0.090 |
Why?
| | Tunica Intima | 3 | 2015 | 32 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2014 | 494 | 0.090 |
Why?
| | Mucus | 1 | 2008 | 9 | 0.090 |
Why?
| | HIV Envelope Protein gp120 | 3 | 2006 | 20 | 0.090 |
Why?
| | Chemokines, CC | 1 | 2008 | 8 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 387 | 0.090 |
Why?
| | Epitopes | 5 | 2017 | 89 | 0.090 |
Why?
| | Flaviviridae | 2 | 1998 | 2 | 0.090 |
Why?
| | Serologic Tests | 2 | 2022 | 15 | 0.090 |
Why?
| | Urine | 1 | 1988 | 10 | 0.090 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2008 | 2 | 0.090 |
Why?
| | Hemophilia A | 3 | 1983 | 43 | 0.090 |
Why?
| | Urogenital System | 1 | 2008 | 2 | 0.090 |
Why?
| | Ganciclovir | 2 | 1998 | 26 | 0.080 |
Why?
| | Chlamydia trachomatis | 1 | 2008 | 17 | 0.080 |
Why?
| | Brain | 1 | 2018 | 1756 | 0.080 |
Why?
| | HLA-B Antigens | 2 | 2007 | 10 | 0.080 |
Why?
| | South Africa | 2 | 2018 | 17 | 0.080 |
Why?
| | Feedback, Physiological | 1 | 2008 | 21 | 0.080 |
Why?
| | Cyclooxygenase 2 | 1 | 2008 | 32 | 0.080 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 6 | 0.080 |
Why?
| | Candida | 3 | 2009 | 17 | 0.080 |
Why?
| | Ki-67 Antigen | 1 | 2007 | 13 | 0.080 |
Why?
| | Skin | 2 | 2006 | 136 | 0.080 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 1 | 2007 | 1 | 0.080 |
Why?
| | Heterosexuality | 1 | 2007 | 3 | 0.080 |
Why?
| | Fibrin Fibrinogen Degradation Products | 3 | 2012 | 13 | 0.080 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 157 | 0.080 |
Why?
| | Unsafe Sex | 1 | 2007 | 7 | 0.080 |
Why?
| | Uterine Cervical Diseases | 1 | 2007 | 4 | 0.080 |
Why?
| | Quality Assurance, Health Care | 1 | 2008 | 56 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2008 | 62 | 0.080 |
Why?
| | Drug Hypersensitivity | 1 | 2007 | 19 | 0.080 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 3 | 2006 | 5 | 0.080 |
Why?
| | Chemokines, CXC | 1 | 2007 | 7 | 0.080 |
Why?
| | Stavudine | 1 | 2007 | 1 | 0.080 |
Why?
| | Receptors, Prostaglandin | 1 | 2007 | 2 | 0.080 |
Why?
| | Mutation | 4 | 2003 | 464 | 0.080 |
Why?
| | Interleukin-18 | 1 | 2007 | 12 | 0.080 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2007 | 26 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2008 | 128 | 0.080 |
Why?
| | Diagnostic Services | 1 | 2006 | 1 | 0.080 |
Why?
| | AIDS Serodiagnosis | 1 | 2006 | 6 | 0.080 |
Why?
| | Interleukin-1 | 2 | 2005 | 91 | 0.080 |
Why?
| | Neurodegenerative Diseases | 1 | 2008 | 124 | 0.080 |
Why?
| | Bone Marrow Transplantation | 1 | 1987 | 41 | 0.080 |
Why?
| | Neuropsychological Tests | 2 | 2022 | 1314 | 0.080 |
Why?
| | Socioeconomic Factors | 2 | 2019 | 364 | 0.080 |
Why?
| | Endothelial Cells | 2 | 2023 | 72 | 0.080 |
Why?
| | Blood | 2 | 2019 | 29 | 0.070 |
Why?
| | Myeloid Progenitor Cells | 1 | 2006 | 2 | 0.070 |
Why?
| | Immunoglobulin Allotypes | 1 | 1986 | 1 | 0.070 |
Why?
| | Immunoglobulin Idiotypes | 1 | 1986 | 4 | 0.070 |
Why?
| | Major Histocompatibility Complex | 2 | 1983 | 15 | 0.070 |
Why?
| | Sjogren's Syndrome | 1 | 1986 | 3 | 0.070 |
Why?
| | Blood Preservation | 1 | 2006 | 5 | 0.070 |
Why?
| | Centrifugation, Density Gradient | 1 | 2006 | 15 | 0.070 |
Why?
| | Enterobacteriaceae | 1 | 2006 | 39 | 0.070 |
Why?
| | Intermediate Filaments | 1 | 1986 | 18 | 0.070 |
Why?
| | Langerhans Cells | 1 | 2006 | 3 | 0.070 |
Why?
| | Reference Values | 5 | 2006 | 250 | 0.070 |
Why?
| | Lectins, C-Type | 2 | 2022 | 144 | 0.070 |
Why?
| | Phagocytosis | 2 | 2021 | 58 | 0.070 |
Why?
| | Cytoskeleton | 1 | 1986 | 66 | 0.070 |
Why?
| | Placebos | 2 | 2016 | 83 | 0.070 |
Why?
| | NFATC Transcription Factors | 1 | 2006 | 18 | 0.070 |
Why?
| | Statistics, Nonparametric | 2 | 2003 | 156 | 0.070 |
Why?
| | Research Design | 1 | 2008 | 244 | 0.070 |
Why?
| | Lymphokines | 2 | 2001 | 9 | 0.070 |
Why?
| | Protein Precursors | 2 | 2021 | 21 | 0.070 |
Why?
| | Liver | 2 | 2019 | 214 | 0.070 |
Why?
| | Penis | 2 | 2006 | 68 | 0.070 |
Why?
| | Rats, Inbred F344 | 3 | 1983 | 51 | 0.070 |
Why?
| | Receptors, Complement | 3 | 1995 | 5 | 0.070 |
Why?
| | Cell Lineage | 2 | 2015 | 34 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 563 | 0.070 |
Why?
| | Drug Combinations | 2 | 2016 | 89 | 0.070 |
Why?
| | Isoantigens | 4 | 2000 | 5 | 0.070 |
Why?
| | Ficoll | 2 | 2006 | 2 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2018 | 139 | 0.070 |
Why?
| | Gene Expression | 2 | 2023 | 267 | 0.070 |
Why?
| | Severity of Illness Index | 3 | 2021 | 1242 | 0.070 |
Why?
| | Ribavirin | 2 | 2016 | 32 | 0.060 |
Why?
| | Glycoproteins | 2 | 2015 | 64 | 0.060 |
Why?
| | Glycosylation | 2 | 2020 | 28 | 0.060 |
Why?
| | Lysosomes | 1 | 1984 | 26 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2004 | 24 | 0.060 |
Why?
| | Papillomaviridae | 2 | 2007 | 30 | 0.060 |
Why?
| | Genes, MDR | 1 | 2003 | 1 | 0.060 |
Why?
| | Luteal Phase | 2 | 2000 | 7 | 0.060 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 29 | 0.060 |
Why?
| | Human T-lymphotropic virus 1 | 2 | 1995 | 12 | 0.060 |
Why?
| | Telomere | 2 | 2003 | 8 | 0.060 |
Why?
| | DNA, Mitochondrial | 1 | 2003 | 10 | 0.060 |
Why?
| | NAD+ Nucleosidase | 2 | 2000 | 2 | 0.060 |
Why?
| | Integrins | 1 | 2023 | 29 | 0.060 |
Why?
| | Hemoglobins | 1 | 2004 | 85 | 0.060 |
Why?
| | Chicago | 3 | 2017 | 957 | 0.060 |
Why?
| | Hepatitis A Vaccines | 3 | 2014 | 3 | 0.060 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2003 | 25 | 0.060 |
Why?
| | Vaginal Smears | 1 | 2003 | 18 | 0.060 |
Why?
| | Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 4 | 0.060 |
Why?
| | Immunohistochemistry | 3 | 2016 | 471 | 0.060 |
Why?
| | Transcription Factor AP-1 | 3 | 1999 | 17 | 0.060 |
Why?
| | NAD | 1 | 2022 | 7 | 0.060 |
Why?
| | Natural Killer T-Cells | 2 | 2016 | 5 | 0.060 |
Why?
| | Nucleocapsid | 1 | 2022 | 3 | 0.060 |
Why?
| | Bayes Theorem | 1 | 2023 | 49 | 0.060 |
Why?
| | Coronary Vessels | 1 | 2023 | 56 | 0.060 |
Why?
| | Single-Cell Analysis | 1 | 2022 | 7 | 0.060 |
Why?
| | Liver Diseases | 2 | 2015 | 47 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 4 | 2007 | 9 | 0.060 |
Why?
| | Sequence Analysis, RNA | 1 | 2022 | 43 | 0.060 |
Why?
| | RNA | 1 | 2022 | 45 | 0.060 |
Why?
| | Proteomics | 1 | 2023 | 91 | 0.060 |
Why?
| | Feces | 2 | 2017 | 98 | 0.060 |
Why?
| | Drug Resistance, Microbial | 2 | 2000 | 96 | 0.060 |
Why?
| | Puerto Rico | 2 | 2016 | 15 | 0.060 |
Why?
| | Enhancer Elements, Genetic | 2 | 1999 | 11 | 0.060 |
Why?
| | Verbal Learning | 1 | 2022 | 42 | 0.060 |
Why?
| | Immunoenzyme Techniques | 4 | 1998 | 49 | 0.060 |
Why?
| | Proteinuria | 1 | 2023 | 126 | 0.050 |
Why?
| | Genes, gag | 1 | 2002 | 3 | 0.050 |
Why?
| | Mental Recall | 1 | 2022 | 77 | 0.050 |
Why?
| | Longevity | 1 | 2022 | 33 | 0.050 |
Why?
| | Complement C3 | 2 | 1993 | 9 | 0.050 |
Why?
| | Citric Acid | 1 | 2021 | 3 | 0.050 |
Why?
| | Haplorhini | 1 | 2021 | 13 | 0.050 |
Why?
| | Haptoglobins | 1 | 2021 | 5 | 0.050 |
Why?
| | Mitogens | 2 | 1996 | 7 | 0.050 |
Why?
| | Rats, Inbred Strains | 1 | 1981 | 46 | 0.050 |
Why?
| | Survivors | 1 | 2022 | 78 | 0.050 |
Why?
| | Reference Standards | 2 | 2008 | 36 | 0.050 |
Why?
| | Games, Experimental | 1 | 2021 | 9 | 0.050 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 2 | 1999 | 11 | 0.050 |
Why?
| | Tight Junctions | 1 | 2021 | 30 | 0.050 |
Why?
| | Public Health | 1 | 2022 | 69 | 0.050 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2021 | 10 | 0.050 |
Why?
| | Blood Cell Count | 2 | 2008 | 18 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 2022 | 91 | 0.050 |
Why?
| | Urbanization | 1 | 2021 | 3 | 0.050 |
Why?
| | Immunologic Techniques | 1 | 2001 | 5 | 0.050 |
Why?
| | Dust | 1 | 2021 | 6 | 0.050 |
Why?
| | Phosphatidylcholines | 1 | 2021 | 7 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 320 | 0.050 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 18 | 0.050 |
Why?
| | Vital Capacity | 1 | 2021 | 11 | 0.050 |
Why?
| | Receptors, Complement 3d | 4 | 1995 | 4 | 0.050 |
Why?
| | Growth Inhibitors | 1 | 2001 | 14 | 0.050 |
Why?
| | Lymph Nodes | 2 | 1999 | 84 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 39 | 0.050 |
Why?
| | Geriatric Assessment | 1 | 2022 | 227 | 0.050 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2000 | 5 | 0.050 |
Why?
| | Permeability | 1 | 2021 | 138 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2021 | 29 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2021 | 36 | 0.050 |
Why?
| | Disease Reservoirs | 1 | 2000 | 10 | 0.050 |
Why?
| | Follicular Phase | 1 | 2000 | 3 | 0.050 |
Why?
| | Drug Design | 1 | 2001 | 33 | 0.050 |
Why?
| | Memory Disorders | 1 | 2022 | 181 | 0.050 |
Why?
| | Estradiol | 1 | 2000 | 61 | 0.050 |
Why?
| | Disease Management | 1 | 2022 | 138 | 0.050 |
Why?
| | Lung Diseases | 1 | 2021 | 54 | 0.050 |
Why?
| | Indinavir | 1 | 2000 | 2 | 0.050 |
Why?
| | L-Selectin | 1 | 2000 | 13 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2020 | 8 | 0.050 |
Why?
| | Kinetics | 2 | 1999 | 263 | 0.050 |
Why?
| | Viral Hepatitis Vaccines | 1 | 2000 | 1 | 0.050 |
Why?
| | Mumps virus | 1 | 2000 | 1 | 0.050 |
Why?
| | Leukapheresis | 1 | 2000 | 2 | 0.050 |
Why?
| | Glycolysis | 1 | 2020 | 22 | 0.050 |
Why?
| | Memory | 1 | 2022 | 335 | 0.050 |
Why?
| | HIV Fusion Inhibitors | 2 | 2013 | 3 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 45 | 0.050 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2000 | 8 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2000 | 15 | 0.050 |
Why?
| | Program Development | 1 | 2000 | 75 | 0.050 |
Why?
| | Evaluation Studies as Topic | 3 | 1995 | 61 | 0.050 |
Why?
| | Electrocardiography | 1 | 2021 | 230 | 0.050 |
Why?
| | Gene Products, env | 2 | 1999 | 13 | 0.050 |
Why?
| | Drug Synergism | 2 | 1998 | 67 | 0.050 |
Why?
| | Boston | 1 | 2019 | 28 | 0.050 |
Why?
| | Glutathione | 1 | 2019 | 31 | 0.050 |
Why?
| | Glutamine | 1 | 2019 | 12 | 0.050 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 224 | 0.050 |
Why?
| | Serine Endopeptidases | 1 | 1999 | 18 | 0.050 |
Why?
| | Virulence | 1 | 1999 | 15 | 0.050 |
Why?
| | Bacterial Vaccines | 1 | 1999 | 4 | 0.050 |
Why?
| | Glutamic Acid | 1 | 2019 | 36 | 0.050 |
Why?
| | Neuropsychology | 1 | 2019 | 12 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 1999 | 7 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2000 | 297 | 0.050 |
Why?
| | Genes | 3 | 1988 | 9 | 0.040 |
Why?
| | Pneumococcal Infections | 1 | 1999 | 9 | 0.040 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2019 | 51 | 0.040 |
Why?
| | Th1 Cells | 1 | 1999 | 32 | 0.040 |
Why?
| | Leukemia | 4 | 1987 | 10 | 0.040 |
Why?
| | Occupational Diseases | 1 | 1999 | 27 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 1999 | 38 | 0.040 |
Why?
| | Educational Status | 1 | 2020 | 304 | 0.040 |
Why?
| | Epitope Mapping | 1 | 2018 | 3 | 0.040 |
Why?
| | Freund's Adjuvant | 1 | 2018 | 2 | 0.040 |
Why?
| | Vaginitis | 1 | 1998 | 3 | 0.040 |
Why?
| | Aortic Diseases | 1 | 2018 | 10 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2019 | 141 | 0.040 |
Why?
| | Rats | 5 | 1986 | 972 | 0.040 |
Why?
| | Pneumonia, Pneumocystis | 2 | 1993 | 32 | 0.040 |
Why?
| | Obesity | 1 | 2022 | 359 | 0.040 |
Why?
| | Receptors, Chemokine | 1 | 1998 | 13 | 0.040 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 18 | 0.040 |
Why?
| | Aorta | 1 | 2018 | 33 | 0.040 |
Why?
| | Bone Development | 1 | 2018 | 34 | 0.040 |
Why?
| | Hepatitis Antibodies | 1 | 1998 | 1 | 0.040 |
Why?
| | Age Distribution | 2 | 2008 | 109 | 0.040 |
Why?
| | Veterans | 1 | 2020 | 96 | 0.040 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 1998 | 8 | 0.040 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 1 | 2018 | 3 | 0.040 |
Why?
| | Jurkat Cells | 2 | 2013 | 11 | 0.040 |
Why?
| | AIDS-Associated Nephropathy | 1 | 2018 | 8 | 0.040 |
Why?
| | Genitalia | 1 | 2017 | 2 | 0.040 |
Why?
| | Gastrointestinal Diseases | 2 | 2015 | 47 | 0.040 |
Why?
| | Heating | 1 | 1997 | 4 | 0.040 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2017 | 3 | 0.040 |
Why?
| | Ubiquitins | 1 | 2017 | 9 | 0.040 |
Why?
| | Antibody Affinity | 1 | 2017 | 3 | 0.040 |
Why?
| | Colitis | 1 | 2017 | 39 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2018 | 71 | 0.040 |
Why?
| | STAT5 Transcription Factor | 1 | 2017 | 2 | 0.040 |
Why?
| | Maternal-Fetal Exchange | 1 | 1997 | 12 | 0.040 |
Why?
| | Galectin 3 | 1 | 2017 | 4 | 0.040 |
Why?
| | Endopeptidases | 1 | 1997 | 56 | 0.040 |
Why?
| | Pathology, Clinical | 2 | 1987 | 3 | 0.040 |
Why?
| | Mice, Inbred BALB C | 3 | 1991 | 292 | 0.040 |
Why?
| | Autoimmune Diseases | 2 | 2016 | 67 | 0.040 |
Why?
| | Clone Cells | 3 | 2003 | 21 | 0.040 |
Why?
| | Decision Trees | 2 | 2006 | 18 | 0.040 |
Why?
| | Interferons | 1 | 2016 | 14 | 0.040 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2016 | 2 | 0.040 |
Why?
| | Germinal Center | 1 | 2016 | 2 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 4 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 8 | 0.040 |
Why?
| | Indomethacin | 1 | 1996 | 9 | 0.040 |
Why?
| | Dinoprostone | 1 | 1996 | 33 | 0.040 |
Why?
| | Antigen-Antibody Reactions | 2 | 1988 | 9 | 0.040 |
Why?
| | Reproductive Tract Infections | 1 | 2016 | 1 | 0.040 |
Why?
| | Sulfoxides | 1 | 2016 | 6 | 0.040 |
Why?
| | Cost of Illness | 2 | 2006 | 66 | 0.040 |
Why?
| | Sleep | 1 | 2020 | 390 | 0.040 |
Why?
| | Receptors, Interleukin-1 | 1 | 1996 | 7 | 0.040 |
Why?
| | Electroporation | 1 | 2016 | 3 | 0.040 |
Why?
| | Sulfasalazine | 1 | 2016 | 4 | 0.040 |
Why?
| | Probiotics | 1 | 2016 | 18 | 0.040 |
Why?
| | Respiratory Mucosa | 1 | 2016 | 6 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2016 | 42 | 0.040 |
Why?
| | Viruses | 1 | 2016 | 7 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 35 | 0.040 |
Why?
| | Biofilms | 1 | 2016 | 17 | 0.040 |
Why?
| | N-Glycosyl Hydrolases | 1 | 1995 | 1 | 0.040 |
Why?
| | Neurons | 1 | 2019 | 409 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 899 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 1996 | 157 | 0.040 |
Why?
| | Accidents, Occupational | 1 | 1995 | 3 | 0.030 |
Why?
| | Injections, Subcutaneous | 2 | 2007 | 37 | 0.030 |
Why?
| | Medical Waste | 1 | 1995 | 2 | 0.030 |
Why?
| | Cervix Mucus | 1 | 2015 | 5 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 81 | 0.030 |
Why?
| | Retroviridae Infections | 1 | 1995 | 1 | 0.030 |
Why?
| | Spumavirus | 1 | 1995 | 1 | 0.030 |
Why?
| | Prevotella | 1 | 2015 | 2 | 0.030 |
Why?
| | Ruminococcus | 1 | 2015 | 2 | 0.030 |
Why?
| | Graves Disease | 1 | 1995 | 4 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2016 | 311 | 0.030 |
Why?
| | Hypersensitivity | 1 | 2016 | 58 | 0.030 |
Why?
| | Complement C4b | 1 | 1995 | 3 | 0.030 |
Why?
| | MEDLINE | 1 | 2015 | 7 | 0.030 |
Why?
| | Receptors, Complement 3b | 1 | 1995 | 15 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2016 | 91 | 0.030 |
Why?
| | Color | 1 | 1995 | 9 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 56 | 0.030 |
Why?
| | Transcription Factors | 1 | 2016 | 178 | 0.030 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 1996 | 50 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2015 | 34 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2015 | 20 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2022 | 1119 | 0.030 |
Why?
| | Illinois | 1 | 2016 | 267 | 0.030 |
Why?
| | Aspirin | 1 | 2016 | 97 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2016 | 90 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 3 | 1989 | 43 | 0.030 |
Why?
| | Circumcision, Male | 2 | 2006 | 7 | 0.030 |
Why?
| | Histocytochemistry | 2 | 1984 | 34 | 0.030 |
Why?
| | Hydrolysis | 1 | 2014 | 14 | 0.030 |
Why?
| | Quality of Life | 1 | 2020 | 750 | 0.030 |
Why?
| | Survival Analysis | 1 | 2015 | 372 | 0.030 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 47 | 0.030 |
Why?
| | World Health Organization | 1 | 2014 | 18 | 0.030 |
Why?
| | Calibration | 2 | 1995 | 25 | 0.030 |
Why?
| | Containment of Biohazards | 1 | 1994 | 1 | 0.030 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2014 | 20 | 0.030 |
Why?
| | Antigens, Neoplasm | 1 | 2014 | 44 | 0.030 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2014 | 11 | 0.030 |
Why?
| | Hemolysis | 1 | 1994 | 10 | 0.030 |
Why?
| | Blood Cells | 1 | 1994 | 6 | 0.030 |
Why?
| | Elasticity Imaging Techniques | 1 | 2013 | 10 | 0.030 |
Why?
| | Cytidine Deaminase | 1 | 2013 | 1 | 0.030 |
Why?
| | Eye | 1 | 2013 | 8 | 0.030 |
Why?
| | Digestive System | 1 | 2013 | 17 | 0.030 |
Why?
| | Pore Forming Cytotoxic Proteins | 2 | 2006 | 3 | 0.030 |
Why?
| | Perforin | 2 | 2006 | 4 | 0.030 |
Why?
| | Synovial Fluid | 2 | 1991 | 137 | 0.030 |
Why?
| | Alleles | 2 | 2004 | 231 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2014 | 126 | 0.030 |
Why?
| | Cathelicidins | 1 | 2013 | 1 | 0.030 |
Why?
| | beta-Defensins | 1 | 2013 | 2 | 0.030 |
Why?
| | Pathology | 1 | 1993 | 4 | 0.030 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2013 | 3 | 0.030 |
Why?
| | Immunoblotting | 1 | 2013 | 65 | 0.030 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 1993 | 4 | 0.030 |
Why?
| | Nucleic Acid Hybridization | 1 | 1993 | 12 | 0.030 |
Why?
| | Fixatives | 1 | 1993 | 7 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 467 | 0.030 |
Why?
| | Kidney Diseases | 1 | 2015 | 152 | 0.030 |
Why?
| | Demography | 1 | 2013 | 83 | 0.030 |
Why?
| | Scattering, Radiation | 1 | 1993 | 41 | 0.030 |
Why?
| | Fibroblasts | 1 | 2013 | 104 | 0.030 |
Why?
| | Observer Variation | 1 | 1993 | 142 | 0.030 |
Why?
| | Crosses, Genetic | 2 | 1983 | 15 | 0.030 |
Why?
| | Postmortem Changes | 1 | 1992 | 35 | 0.030 |
Why?
| | Ascitic Fluid | 2 | 1983 | 9 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 1993 | 59 | 0.030 |
Why?
| | Toll-Like Receptor 3 | 1 | 2012 | 1 | 0.030 |
Why?
| | Polypharmacy | 1 | 2012 | 10 | 0.030 |
Why?
| | Cercocebus | 1 | 2012 | 2 | 0.030 |
Why?
| | Fibrinogen | 1 | 2012 | 32 | 0.030 |
Why?
| | Lymphoma | 3 | 1987 | 63 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2007 | 234 | 0.030 |
Why?
| | Thrombin | 1 | 2012 | 14 | 0.030 |
Why?
| | Antithrombins | 1 | 2012 | 6 | 0.030 |
Why?
| | Needs Assessment | 1 | 2012 | 50 | 0.030 |
Why?
| | Neurofibrillary Tangles | 1 | 2013 | 181 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2012 | 70 | 0.030 |
Why?
| | Cell Culture Techniques | 2 | 2003 | 49 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 56 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 1991 | 7 | 0.030 |
Why?
| | Retroviridae | 2 | 1999 | 6 | 0.030 |
Why?
| | Hot Temperature | 2 | 2008 | 26 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2011 | 23 | 0.030 |
Why?
| | Life Style | 1 | 2013 | 226 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2012 | 77 | 0.030 |
Why?
| | Synovitis | 1 | 1991 | 22 | 0.030 |
Why?
| | Complement C1q | 1 | 1991 | 5 | 0.030 |
Why?
| | Fetal Blood | 2 | 2003 | 17 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2012 | 72 | 0.030 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2011 | 7 | 0.030 |
Why?
| | AIDS-Related Complex | 1 | 1991 | 4 | 0.030 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 1988 | 6 | 0.030 |
Why?
| | Amyloid beta-Peptides | 1 | 2013 | 294 | 0.030 |
Why?
| | Fetal Proteins | 1 | 2011 | 2 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2011 | 6 | 0.030 |
Why?
| | Models, Immunological | 1 | 2011 | 9 | 0.030 |
Why?
| | Algorithms | 1 | 2014 | 429 | 0.030 |
Why?
| | Societies, Medical | 1 | 1993 | 214 | 0.030 |
Why?
| | Thrombocytopenia | 2 | 1988 | 31 | 0.030 |
Why?
| | Herpesvirus 6, Human | 1 | 1990 | 4 | 0.020 |
Why?
| | Microscopy, Fluorescence | 2 | 1998 | 98 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2011 | 73 | 0.020 |
Why?
| | Fatty Acids | 1 | 2010 | 47 | 0.020 |
Why?
| | Models, Statistical | 1 | 2011 | 145 | 0.020 |
Why?
| | Lymphocytes, Null | 1 | 1989 | 1 | 0.020 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2009 | 7 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 1990 | 79 | 0.020 |
Why?
| | Fluoresceins | 1 | 1989 | 11 | 0.020 |
Why?
| | Blood Bactericidal Activity | 1 | 1989 | 5 | 0.020 |
Why?
| | Granulomatous Disease, Chronic | 1 | 1989 | 7 | 0.020 |
Why?
| | Single-Blind Method | 1 | 1989 | 130 | 0.020 |
Why?
| | Immunoglobulin M | 2 | 1986 | 23 | 0.020 |
Why?
| | Nervous System Diseases | 1 | 2011 | 159 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 137 | 0.020 |
Why?
| | RNA, Bacterial | 1 | 2009 | 3 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2009 | 16 | 0.020 |
Why?
| | 2,2'-Dipyridyl | 1 | 2009 | 1 | 0.020 |
Why?
| | Mycobacterium avium Complex | 1 | 2009 | 2 | 0.020 |
Why?
| | Disinfectants | 1 | 2009 | 9 | 0.020 |
Why?
| | Disulfides | 1 | 2009 | 17 | 0.020 |
Why?
| | Drug Stability | 1 | 2008 | 10 | 0.020 |
Why?
| | Immunoglobulin Switch Region | 1 | 1988 | 1 | 0.020 |
Why?
| | Retroviridae Proteins | 1 | 1988 | 2 | 0.020 |
Why?
| | HeLa Cells | 1 | 2008 | 58 | 0.020 |
Why?
| | Species Specificity | 2 | 1991 | 76 | 0.020 |
Why?
| | Cell Adhesion Molecules | 1 | 2008 | 43 | 0.020 |
Why?
| | New South Wales | 1 | 2008 | 4 | 0.020 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2008 | 9 | 0.020 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2008 | 9 | 0.020 |
Why?
| | Carmustine | 2 | 1979 | 8 | 0.020 |
Why?
| | Lymphocytosis | 1 | 1988 | 1 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 2001 | 245 | 0.020 |
Why?
| | Cognition | 1 | 2017 | 1330 | 0.020 |
Why?
| | North America | 1 | 2008 | 42 | 0.020 |
Why?
| | ROC Curve | 1 | 2008 | 155 | 0.020 |
Why?
| | Chemokine CXCL1 | 1 | 2007 | 3 | 0.020 |
Why?
| | Immunoglobulin Isotypes | 1 | 1987 | 8 | 0.020 |
Why?
| | Immunoglobulin Light Chains | 1 | 1987 | 9 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2007 | 37 | 0.020 |
Why?
| | Organ Culture Techniques | 1 | 2007 | 41 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2007 | 32 | 0.020 |
Why?
| | Culture Media | 1 | 2007 | 44 | 0.020 |
Why?
| | Corynebacterium | 1 | 2007 | 5 | 0.020 |
Why?
| | Leukemia, Lymphoid | 1 | 1987 | 2 | 0.020 |
Why?
| | Interleukin-23 | 1 | 2007 | 14 | 0.020 |
Why?
| | Leukemia, Myeloid | 1 | 1987 | 5 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2007 | 9 | 0.020 |
Why?
| | Endosomes | 1 | 2007 | 8 | 0.020 |
Why?
| | Interleukin-1alpha | 1 | 2007 | 5 | 0.020 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2007 | 20 | 0.020 |
Why?
| | Stromal Cells | 1 | 2007 | 40 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2007 | 42 | 0.020 |
Why?
| | Anemia, Aplastic | 1 | 1987 | 2 | 0.020 |
Why?
| | Karyotyping | 1 | 1987 | 13 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 87 | 0.020 |
Why?
| | Cercocebus atys | 1 | 2006 | 1 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2007 | 39 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2007 | 128 | 0.020 |
Why?
| | Blood Donors | 2 | 1998 | 7 | 0.020 |
Why?
| | Syphilis | 1 | 2006 | 6 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1986 | 18 | 0.020 |
Why?
| | Gonorrhea | 1 | 2006 | 8 | 0.020 |
Why?
| | Bacteriological Techniques | 1 | 2006 | 20 | 0.020 |
Why?
| | Receptors, Interleukin-15 | 1 | 2006 | 3 | 0.020 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2006 | 9 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 1989 | 153 | 0.020 |
Why?
| | Paraproteins | 1 | 1986 | 2 | 0.020 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 1986 | 6 | 0.020 |
Why?
| | Viral Matrix Proteins | 1 | 2006 | 4 | 0.020 |
Why?
| | Histological Techniques | 1 | 1986 | 7 | 0.020 |
Why?
| | Bone Marrow | 1 | 1987 | 78 | 0.020 |
Why?
| | Logistic Models | 1 | 2008 | 474 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2006 | 34 | 0.020 |
Why?
| | CpG Islands | 1 | 2006 | 53 | 0.020 |
Why?
| | Swine | 1 | 1986 | 117 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 90 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2006 | 107 | 0.020 |
Why?
| | Dementia | 1 | 2011 | 568 | 0.020 |
Why?
| | Antigens, Ly | 1 | 1985 | 2 | 0.020 |
Why?
| | Autoantibodies | 1 | 1986 | 119 | 0.020 |
Why?
| | Organ Size | 1 | 2005 | 119 | 0.020 |
Why?
| | Receptors, KIR | 1 | 2004 | 2 | 0.020 |
Why?
| | Receptors, KIR3DL1 | 1 | 2004 | 2 | 0.020 |
Why?
| | Naphthol AS D Esterase | 1 | 1984 | 1 | 0.020 |
Why?
| | Acid Phosphatase | 1 | 1984 | 4 | 0.020 |
Why?
| | Gene Frequency | 1 | 2004 | 83 | 0.020 |
Why?
| | Immunization Schedule | 1 | 2004 | 1 | 0.020 |
Why?
| | Immunization, Secondary | 1 | 2004 | 7 | 0.020 |
Why?
| | Vaccines, Synthetic | 1 | 2004 | 4 | 0.020 |
Why?
| | Thailand | 1 | 2004 | 14 | 0.020 |
Why?
| | Models, Molecular | 1 | 2004 | 99 | 0.020 |
Why?
| | Costs and Cost Analysis | 1 | 2004 | 39 | 0.020 |
Why?
| | Rats, Inbred BN | 1 | 1983 | 4 | 0.020 |
Why?
| | Rats, Inbred Lew | 1 | 1983 | 13 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 51 | 0.020 |
Why?
| | RNA, Ribosomal, 18S | 1 | 2003 | 2 | 0.020 |
Why?
| | Hepatitis B virus | 1 | 1983 | 7 | 0.010 |
Why?
| | Genetic Markers | 1 | 2003 | 64 | 0.010 |
Why?
| | Mycobacterium Infections | 1 | 1983 | 4 | 0.010 |
Why?
| | Antigens, CD1d | 1 | 2003 | 3 | 0.010 |
Why?
| | Graft Rejection | 1 | 1983 | 87 | 0.010 |
Why?
| | Hepatitis B Vaccines | 1 | 2003 | 7 | 0.010 |
Why?
| | Factor VIII | 1 | 1983 | 28 | 0.010 |
Why?
| | Genetic Variation | 1 | 2003 | 107 | 0.010 |
Why?
| | Culture Techniques | 1 | 2002 | 38 | 0.010 |
Why?
| | Drug Interactions | 1 | 2002 | 70 | 0.010 |
Why?
| | Blood Component Removal | 1 | 2002 | 1 | 0.010 |
Why?
| | Odds Ratio | 1 | 2003 | 321 | 0.010 |
Why?
| | Biological Factors | 1 | 2001 | 9 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2001 | 38 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1981 | 26 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2002 | 221 | 0.010 |
Why?
| | Receptors, OSM-LIF | 1 | 2001 | 1 | 0.010 |
Why?
| | Leukemia Inhibitory Factor Receptor alpha Subunit | 1 | 2001 | 1 | 0.010 |
Why?
| | Contactins | 1 | 2001 | 1 | 0.010 |
Why?
| | Leukemia Inhibitory Factor | 1 | 2001 | 3 | 0.010 |
Why?
| | Receptors, Cytokine | 1 | 2001 | 4 | 0.010 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 2001 | 2 | 0.010 |
Why?
| | HIV Envelope Protein gp160 | 1 | 2000 | 3 | 0.010 |
Why?
| | Abortion, Spontaneous | 1 | 2000 | 9 | 0.010 |
Why?
| | Pokeweed Mitogens | 1 | 2000 | 1 | 0.010 |
Why?
| | Streptokinase | 1 | 2000 | 2 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2002 | 282 | 0.010 |
Why?
| | Mice, SCID | 1 | 2000 | 64 | 0.010 |
Why?
| | Transportation | 1 | 2000 | 6 | 0.010 |
Why?
| | Structure-Activity Relationship | 2 | 1993 | 53 | 0.010 |
Why?
| | Injections, Intradermal | 1 | 2000 | 2 | 0.010 |
Why?
| | HIV Reverse Transcriptase | 1 | 2000 | 10 | 0.010 |
Why?
| | HIV Protease | 1 | 2000 | 9 | 0.010 |
Why?
| | Tomography | 1 | 2000 | 14 | 0.010 |
Why?
| | Granzymes | 1 | 1999 | 8 | 0.010 |
Why?
| | Mycoplasma | 1 | 1999 | 4 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1999 | 8 | 0.010 |
Why?
| | Chemical Fractionation | 1 | 1999 | 7 | 0.010 |
Why?
| | Premedication | 1 | 1999 | 6 | 0.010 |
Why?
| | Pneumococcal Vaccines | 1 | 1999 | 5 | 0.010 |
Why?
| | Hepatitis B Surface Antigens | 1 | 1998 | 10 | 0.010 |
Why?
| | Ohio | 1 | 1998 | 11 | 0.010 |
Why?
| | Liver Function Tests | 1 | 1998 | 29 | 0.010 |
Why?
| | Databases as Topic | 1 | 1998 | 22 | 0.010 |
Why?
| | Virus Integration | 1 | 1998 | 9 | 0.010 |
Why?
| | Body Temperature | 1 | 1979 | 73 | 0.010 |
Why?
| | Immediate-Early Proteins | 1 | 1998 | 6 | 0.010 |
Why?
| | Protein Binding | 2 | 1991 | 154 | 0.010 |
Why?
| | Fas Ligand Protein | 1 | 1998 | 12 | 0.010 |
Why?
| | Fetus | 1 | 1998 | 66 | 0.010 |
Why?
| | Immunoglobulin Constant Regions | 2 | 1988 | 2 | 0.010 |
Why?
| | Recombination, Genetic | 2 | 1988 | 14 | 0.010 |
Why?
| | Translocation, Genetic | 2 | 1988 | 11 | 0.010 |
Why?
| | Chromosome Deletion | 2 | 1988 | 30 | 0.010 |
Why?
| | Patient Selection | 1 | 2000 | 262 | 0.010 |
Why?
| | Immunoglobulin A, Secretory | 1 | 1997 | 7 | 0.010 |
Why?
| | Molecular Weight | 2 | 1988 | 57 | 0.010 |
Why?
| | Infection Control | 1 | 1999 | 174 | 0.010 |
Why?
| | Propionibacterium acnes | 1 | 1977 | 8 | 0.010 |
Why?
| | Killer Cells, Lymphokine-Activated | 1 | 1997 | 1 | 0.010 |
Why?
| | Luminescent Measurements | 2 | 1986 | 21 | 0.010 |
Why?
| | Lymphotoxin-alpha | 1 | 1996 | 6 | 0.010 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 1996 | 11 | 0.010 |
Why?
| | Drug Eruptions | 1 | 1996 | 12 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1996 | 34 | 0.010 |
Why?
| | HTLV-I Antibodies | 1 | 1995 | 1 | 0.010 |
Why?
| | Cell-Free System | 1 | 1995 | 3 | 0.010 |
Why?
| | HTLV-I Infections | 1 | 1995 | 5 | 0.010 |
Why?
| | Antibodies, Blocking | 1 | 1995 | 9 | 0.010 |
Why?
| | Zalcitabine | 1 | 1995 | 2 | 0.010 |
Why?
| | Needlestick Injuries | 1 | 1995 | 2 | 0.010 |
Why?
| | Antigen-Antibody Complex | 1 | 1995 | 13 | 0.010 |
Why?
| | Complement C4 | 1 | 1995 | 4 | 0.010 |
Why?
| | Antigens, CD19 | 1 | 1995 | 6 | 0.010 |
Why?
| | Fluorescence | 1 | 1995 | 12 | 0.010 |
Why?
| | Tissue Donors | 1 | 1995 | 85 | 0.010 |
Why?
| | Blood-Borne Pathogens | 1 | 1994 | 5 | 0.010 |
Why?
| | Hospitals, University | 1 | 1994 | 44 | 0.010 |
Why?
| | Histocompatibility Antigens | 1 | 1992 | 3 | 0.010 |
Why?
| | Research | 1 | 1992 | 62 | 0.010 |
Why?
| | Guinea Pigs | 1 | 1991 | 65 | 0.010 |
Why?
| | Lymphocyte Cooperation | 1 | 1991 | 2 | 0.010 |
Why?
| | HLA Antigens | 1 | 1991 | 20 | 0.010 |
Why?
| | Lysogeny | 1 | 1990 | 1 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1990 | 1 | 0.010 |
Why?
| | Viral Interference | 1 | 1990 | 1 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 1992 | 463 | 0.010 |
Why?
| | Rabbits | 1 | 1991 | 336 | 0.010 |
Why?
| | Mycoplasma Infections | 1 | 1990 | 3 | 0.010 |
Why?
| | Deltaretrovirus Infections | 1 | 1990 | 2 | 0.010 |
Why?
| | Mental Disorders | 1 | 1992 | 206 | 0.010 |
Why?
| | Gene Rearrangement, B-Lymphocyte | 1 | 1988 | 1 | 0.010 |
Why?
| | Leukemia, B-Cell | 1 | 1988 | 1 | 0.010 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1988 | 3 | 0.010 |
Why?
| | Platelet Count | 1 | 1988 | 23 | 0.010 |
Why?
| | Immunization, Passive | 1 | 1988 | 24 | 0.010 |
Why?
| | Protein Conformation | 1 | 1988 | 87 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 1987 | 6 | 0.010 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1987 | 9 | 0.010 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 1987 | 6 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1987 | 12 | 0.010 |
Why?
| | HLA-DQ Antigens | 1 | 1987 | 8 | 0.000 |
Why?
| | Combined Modality Therapy | 1 | 1988 | 449 | 0.000 |
Why?
| | Zymosan | 1 | 1986 | 6 | 0.000 |
Why?
| | Chromium Radioisotopes | 1 | 1986 | 2 | 0.000 |
Why?
| | Paraffin | 1 | 1986 | 2 | 0.000 |
Why?
| | Diploidy | 1 | 1986 | 4 | 0.000 |
Why?
| | Cell Membrane | 1 | 1985 | 123 | 0.000 |
Why?
| | Mycobacterium avium | 1 | 1983 | 1 | 0.000 |
Why?
| | Herpesvirus 3, Human | 1 | 1983 | 5 | 0.000 |
Why?
| | Simplexvirus | 1 | 1983 | 11 | 0.000 |
Why?
| | Injections, Intraperitoneal | 1 | 1979 | 14 | 0.000 |
Why?
| | Neoplasms, Experimental | 1 | 1977 | 14 | 0.000 |
Why?
|
|
Landay's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|